Decreased levels of soluble amyloid β-protein precursor and β-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 6, Issue 2, 2004, Pages

  Trysberg, Estelle ^a   Höglund, Kina ^a   Svenungsson, Elisabet ^b   Blennow, Kaj ^a   Tarkowski, Andrej ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

amyloid precursor protein; cerebrospinal fluid; neuropsychiatric systemic lupus erythematosus; tau; amyloid protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; SOLUBILITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SOLUBILITY;

EID: 4344586854     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1040     Document Type: Article

References (41)

1. McCune WJ, Golbus J: Neuropsychiatric lupus. Rheum Dis Clin North Am. 1988, 14: 149-167.
2. Hanly JG, Liang MH: Cognitive disorders in systemic lupus erythematosus. Epidemiologic and clinical issues. Ann NY Acad Sci. 1997, 823: 60-68. DOI: 10.1111/j.1749-6632.1997.tb48379.x
3. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB: Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore). 1976, 55: 323-339. DOI: 10.1097/00005792-197607000-00004
4. Croake JW, Pursley M, Hardin JG, Michalski JP: Systemic lupus erythematosus and dementia. Psychol Rep. 1998, 83: 1034- DOI: 10.2466/pr0.1998.83.3.1034
5. Jonsson H, Nived O, Sturfelt G: Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore). 1989, 68: 141-150. DOI: 10.1097/00005792-198905000-00002
6. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med. 1988, 318: 1423-1431. DOI: 10.1056/NEJM198806023182203
7. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE: Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med. 1991, 81: 975-984. DOI: 10.1093/qjmed/81.3.975
8. Oku K, Atsumi T, Furukawa S, Horita T, Sakai Y, Jodo S, Amasaki Y, Ichikawa K, Amengual O, Koike T: Cerebral imaging by magnetic resonance imaging and single photon emission computed tomography in systemic lupus erythematosus with central nervous system involvement. Rheumatology (Oxford). 2003, 42: 773-777. 10.1093/rheumatology/keg216. DOI: 10.1093/rheumatology/keg216
9. Sergent JS, Lockshin MD: Editorial: treatment of central nervous system lupus erythematosus. Ann Intern Med. 1974, 80: 413-414. DOI: 10.7326/0003-4819-80-3-413_2
10. Abel T, Gladman DD, Urowitz MB: Neuropsychiatric lupus. J Rheumatol. 1980, 7: 325-333.
11. Ernerudh J, Olsson T, Lindstrom F, Skogh T: Cerebrospinal fluid immunoglobulin abnormalities in systemic lupus erythematosus. J Neurol Neurosurg Psychiatry. 1985, 48: 807-813. DOI: 10.1136/jnnp.48.8.807
12. Winfield JB, Shaw M, Silverman LM, Eisenberg RA, Wilson HAd, Koffler D: Intrathecal IgG synthesis and blood–brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med. 1983, 74: 837-844. 10.1016/0002-9343(83)91075-6. DOI: 10.1016/0002-9343(83)91075-6
13. Hirohata S, Hirose S, Miyamoto T: Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Their use as estimates of central nervous system disease activity. Arch Intern Med. 1985, 145: 1843-1846. 10.1001/archinte.145.10.1843. DOI: 10.1001/archinte.1985.00360100105017
14. Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D: Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus. 1992, 1: 111-117. DOI: 10.1177/096120339200100209
15. Hirohata S, Tanimoto K, Ito K: Elevation of cerebrospinal fluid interleukin-6 activity in patients with vasculitides and central nervous system involvement. Clin Immunol Immunopathol. 1993, 66: 225-229. 10.1006/clin.1993.1029. DOI: 10.1006/clin.1993.1029
16. Trysberg E, Carlsten H, Tarkowski A: Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus. 2000, 9: 498-503. DOI: 10.1177/096120330000900704
17. Tsai CY, Wu TH, Tsai ST, Chen KH, Thajeb P, Lin WM, Yu HS, Yu CL: Cerebrospinal fluid interleukin-6, prostaglandin E2 and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections. Scand J Rheumatol. 1994, 23: 57-63. DOI: 10.3109/03009749409103028
18. Yeh TS, Wang CR, Jeng GW, Lee GL, Chen MY, Wang GR, Lin KT, Chuang CY, Chen CY: The study of anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with systemic lupus erythematosus and central nervous system involvement. Autoimmunity. 1994, 18: 169-175. DOI: 10.3109/08916939409007993
19. Svenungsson E, Andersson M, Brundin L, van Vollenhoven R, Khademi M, Tarkowski A, Greitz D, Dahlstrom M, Lundberg I, Klareskog L, Olsson T: Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis. 2001, 60: 372-379. 10.1136/ard.60.4.372. DOI: 10.1136/ard.60.4.372
20. Maccioni RB, Cambiazo V: Role of microtubule-associated proteins in the control of microtubule assembly. Physiol Rev. 1995, 75: 835-864.
21. Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, Blennow K: Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis. 2000, 2: 199-206.
22. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P: High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998, 55: 937-945. 10.1001/archneur.55.7.937. DOI: 10.1001/archneur.55.7.937
23. Sjogren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E, Wallin A, Blennow K: The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord. 2001, 12: 257-264. 10.1159/000051268. DOI: 10.1159/000051268
24. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol. 1995, 26: 231-245. DOI: 10.1007/BF02815140
25. Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, Raiha I, Sourander L, Winblad B, Blennow K: Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry. 1998, 64: 298-305. DOI: 10.1136/jnnp.64.3.298
26. Pratt BM, McPherson JM: TGF-beta in the central nervous system: potential roles in ischemic injury and neurodegenerative diseases. Cytokine Growth Factor Rev. 1997, 8: 267-292. 10.1016/S1359-6101(97)00018-X. DOI: 10.1016/S1359-6101(97)00018-X
27. Border WA, Noble NA: TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int. 1997, 51: 1388-1396. DOI: 10.1038/ki.1997.190
28. Pepper MS: Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 1997, 8: 21-43. 10.1016/S1359-6101(96)00048-2. DOI: 10.1016/S1359-6101(96)00048-2
29. Perrella MA, Jain MK, Lee ME: Role of TGF-beta in vascular development and vascular reactivity. Miner Electrolyte Metab. 1998, 24: 136-143. 10.1159/000057361. DOI: 10.1159/000057361
30. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, Kumar P: Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2002, 23: 237-243. 10.1016/S0197-4580(01)00285-8. DOI: 10.1016/S0197-4580(01)00285-8
31. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter] [see comments]. Arthritis Rheum. 1997, 40: 1725- DOI: 10.1002/art.1780400928
32. Trysberg E, Nylén K, Rosengren LE, Tarkowski A: Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003, 48: 2881-2887. 10.1002/art.11279. DOI: 10.1002/art.11279
33. Breitbach SA, Alexander RW, Daltroy LH, Liang MH, Boll TJ, Karlson EW, Partiridge AJ, Roberts WN, Stern SH, Wacholtz MC, Straaton KV: Determinants of cognitive performance in systemic lupus erythematosus. J Clin Exp Neuropsychol. 1998, 20: 157-166. 10.1076/jcen.20.2.157.1166. DOI: 10.1076/jcen.20.2.157.1166
34. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol. 1995, 26: 231-245. DOI: 10.1007/BF02815140
35. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, Cras P: Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993, 61: 1828-1834. DOI: 10.1111/j.1471-4159.1993.tb09823.x
36. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid beta-amyloid(1–42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999, 56: 673-680. 10.1001/archneur.56.6.673. DOI: 10.1001/archneur.56.6.673
37. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E: Standardization of measurement of beta-amyloid(1–42) in cerebrospinal fluid and plasma. Amyloid. 2000, 7: 245-258. DOI: 10.3109/13506120009146438
38. Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Langstrom G, Skoog I, Svennerholm L, Wikkelso C: Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18–88 years of age. Eur Neurol. 1993, 33: 129-133. DOI: 10.1159/000116919
39. Moore BW: A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun. 1965, 19: 739-744. 10.1016/0006-291X(65)90320-7. DOI: 10.1016/0006-291X(65)90320-7
40. Hanly JG, Walsh NM, Sangalang V: Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992, 19: 732-741.
41. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH: Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem. 2003, 278: 31831-31837. 10.1074/jbc.M303592200. DOI: 10.1074/jbc.M303592200